Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M285,028Revenue $M74,331Net Margin (%)22.0Z-Score5.2
Enterprise Value $M270,699EPS $5.7Operating Margin %28.2F-Score7
P/E(ttm))18.0Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book4.110-y EBITDA Growth Rate %4.3Quick Ratio2.0Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %3.5Current Ratio2.4Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %24.9ROA % (ttm)12.3Higher Current Ratio y-yY
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)21.8Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,780ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJohn Hussman 2014-12-31 Add1.19%$96.78 - $109.07
($105.37)
$ 102.51-3%Add 8301.89%111,325
JNJJoel Greenblatt 2014-12-31 Add0.66%$96.78 - $109.07
($105.43)
$ 102.51-3%Add 5420.84%790,529
JNJJohn Rogers 2014-12-31 Add0.11%$96.78 - $109.07
($105.37)
$ 102.51-3%Add 17.8%632,132
JNJHOTCHKIS & WILEY 2014-12-31 Sold Out $96.78 - $109.07
($105.37)
$ 102.51-3%Sold Out0
JNJRobert Olstein 2014-12-31 Reduce-0.17%$96.78 - $109.07
($105.37)
$ 102.51-3%Reduce -14.46%71,000
JNJRichard Perry 2014-12-31 Reduce-0.11%$96.78 - $109.07
($105.37)
$ 102.51-3%Reduce -8.67%312,610
JNJRay Dalio 2014-12-31 Reduce-0.02%$96.78 - $109.07
($105.37)
$ 102.51-3%Reduce -23.64%64,293
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 102.51-1%New holding, 14319 sh.14,319
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 102.51-1%Add 27.77%84,193
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 102.51-1%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 102.51-1%Reduce -99.8%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 102.51-1%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 102.51-1%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 102.51-1%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 102.51-1%Reduce -3.7%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 102.51-1%Sold Out0
JNJJohn Rogers 2014-06-30 Add0.2%$96.54 - $105.76
($101.02)
$ 102.512%Add 42.46%522,727
JNJRichard Pzena 2014-06-30 Add0.17%$96.54 - $105.76
($101.02)
$ 102.512%Add 33.12%1,155,666
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 102.512%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 102.512%Reduce -13.16%3,300,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ John Hussman 2014-12-31111,32501.2+8301.89%
JNJ Joel Greenblatt 2014-12-31790,5290.030.67+5420.84%
JNJ John Rogers 2014-12-31632,1320.020.76+17.8%
JNJ James Barrow 2014-12-3115,491,3860.562.2+0.92%
JNJ Michael Price 2014-12-3135,00000.45
JNJ Tom Gayner 2014-12-31574,2000.021.6
JNJ Richard Snow 2014-12-313,27000.01
JNJ Prem Watsa 2014-12-3182,85000.56
JNJ Warren Buffett 2014-12-31327,1000.010.03
JNJ Brian Rogers 2014-12-314,633,0000.171.7
JNJ Yacktman Focused Fund 2014-12-313,100,0000.113.5
JNJ Yacktman Fund 2014-12-313,900,0000.143.5
JNJ Richard Pzena 2014-12-311,183,9660.040.66-0.04%
JNJ Ken Fisher 2014-12-3110,424,6070.372.3-0.21%
JNJ Ruane Cunniff 2014-12-3175,94600.04-0.41%
JNJ Donald Yacktman 2014-12-318,611,3590.313.7-0.46%
JNJ Tweedy Browne 2014-12-314,142,4450.1511.1-0.52%
JNJ PRIMECAP Management 2014-12-3112,143,4330.441.3-0.61%
JNJ Jean-Marie Eveillard 2014-12-311,616,9270.060.41-2.1%
JNJ Dodge & Cox 2014-12-3144,23500-6.07%
JNJ Mario Gabelli 2014-12-31336,9350.010.18-8.03%
JNJ Richard Perry 2014-12-31312,6100.011.4-8.67%
JNJ Robert Olstein 2014-12-3171,00000.91-14.46%
JNJ Ray Dalio 2014-12-3164,29300.05-23.64%
JNJ HOTCHKIS & WILEY 2014-12-31000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JOHNSON & JOHNSON10% Owner 2014-12-17Sell8,100$7.621245.28view
JOHNSON & JOHNSON10% Owner 2014-12-12Sell5,000$7.511264.98view
JOHNSON & JOHNSON10% Owner 2014-12-10Sell8,300$7.721227.85view
JOHNSON & JOHNSON10% Owner 2014-12-05Sell15,900$7.761221.01view
JOHNSON & JOHNSON10% Owner 2014-12-01Sell1,200$7.541259.55view
JOHNSON & JOHNSON10% Owner 2014-11-26Sell2,000$7.751222.71view
JOHNSON & JOHNSON10% Owner 2014-11-24Sell9,500$8.141159.34view
JOHNSON & JOHNSON10% Owner 2014-11-12Buy40,000$18469.5view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-5.56view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-4.58view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Investing: Keep It Simple – Part 2 Feb 26 2015 
    A Look at SPY´s Value at Risk Feb 27 2015 
    Investing: Keep It Simple Feb 25 2015 
    All Investing Involves Risk Feb 24 2015 
    Johnson & Johnson Has A Potential Buyer For Its Medical Devices Unit Feb 24 2015 
    test Feb 23 2015 
    possible Feb 22 2015 
    possible Feb 22 2015 
    Johnson & Johnson: Why Investors Should Consider This Stock for Long-Term Gains Feb 22 2015 
    Paul Tudor Jones Is Betting on the SPY, Should You? Feb 20 2015 

    More From Our Partners
    Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015 - ZACKS

    More From Other Websites
    Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform... Feb 27 2015
    Who Might Buy Puma Biotechnology? Feb 27 2015
    Cramer: Pharmacyclics-Johnson & Johnson Deal Unlikely at This Price Feb 27 2015
    Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin Feb 27 2015
    Compelling Financial Benefit in Valeant's Latest Buy Feb 27 2015
    Decision on Ebola mass vaccination in August at earliest - WHO Feb 27 2015
    Decision on Ebola mass vaccination in August at earliest - WHO Feb 27 2015
    Decision on widespread Ebola vaccination in August at earliest - WHO Feb 27 2015
    Decision on widespread Ebola vaccination in August at earliest - WHO Feb 27 2015
    10-K for Johnson & Johnson Feb 26 2015
    Idaho House panel endorses banning contact lens price floors Feb 26 2015
    US stocks close narrowly mixed as energy, data weigh Feb 26 2015
    Health Care Stocks Flexing Their Muscle Feb 26 2015
    The single best stock to own today Feb 26 2015
    Medivation Tops Q4 Views On Strong Xtandi Results Feb 26 2015
    Familiar ETF Friend Will Enjoy a Pharmacyclics Sale Feb 26 2015
    Pharmalot, Pharmalittle: We're Reading About Pharmacyclics, Gilead and Much More!! Feb 26 2015
    Exchange-traded funds that hold big pharma Feb 26 2015
    Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015
    Just How Different are These Healthcare ETFs? Feb 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK